As competitive pressure from the post-patent-expiry entry of generics and new brands onto the market mounts, drug product lifecycles are becoming shorter and shorter with lower peak sales – a double edged sword for pharmaceutical companies. In fact, products worth more than $100 billion in sales (1) will be going off-patent and subject to generic incursion between 2008 and 2012. Thus, effective lifecycle management is becoming a must for pharma companies looking to maximize the return on their considerable investment. Continue reading “Is drug lifecycle management the answer to the $100billion question?” »

Faced with dwindling growth rates in the US and Europe, pharmaceutical companies are turning their attention towards emerging pharmaceutical markets whose double-digit growth is fuelled by their recent economic booms. However, although the patient potential of the emerging market countries is enormous, foreign pharma companies are currently tapping into only a fraction of the consumers, due to fairly poor access to drugs in countries like India and China, and to an extent in Russia, Brazil and Turkey.

Continue reading “Despite Challenges- Big Pharma Companies Turn Attention to Emerging Markets” »